Human Embryonic Stem Cell (hESC)-based innovative PluriXcel platforms focus on developing Regenerative Medicine Advanced Therapy (RMAT) targeting serious or life-threatening diseases and conditions in unmet medical needs that have been big challenges for traditional medicine, presenting the hESC therapy products as a novel, advanced therapeutic strategy for a wide range of incurable or hitherto untreatable neurological and heart diseases. PluriXcel is a game-changing enabling technology to provide RMAT products in large quantity and high quality with adequate cellular capacity to regenerate the neuron circuitry and the contractile heart muscle, ensuring high degrees of efficacy and safety of the hESC-derived therapeutic products, thus robust clinical benefit leading to therapies. It not only constitutes clinically representative progresses in both human neuronal and cardiac therapeutic products for treating a wide range of incurable or hitherto untreatable neurological and cardiovascular diseases, but also offers manufacturing innovation for production scale-up and creation of replacement tissue or organ products.
Mending the Broken Heart
Lack of a scalable human cardiac stem cell source with adequate heart muscle regeneration potential remains a major setback for heart replacement, and fabricating a human heart is still beyond reach. PluriXcel-SMI-Heart Platform enables direct conversion of pluripotent hESC uniformly into a large supply of human cardiac stem or precursor cells for heart replacement or bio-fabrication [patent: USPTO# 9,428,731], providing a practical scalable solution for heart regeneration.
Neuron Circuitry Repair
Due to lack of a scalable human neuron source, the need to restore vital tissue and function for a wide range of neurological diseases remains a daunting challenge to conventional drug development. PluriXcel-SMI-Neuron Platform enables direct conversion of pluripotent hESC into a large supply of human neurons for neuron circuitry repair and nerve tissue bio-fabrication [patent: USPTO# 8,716,017], providing a practical scalable solution for CNS regeneration.
About the Founder
Dr. Xuejun H Parsons received her PhD in Biochemistry, Cell and Molecular Biology from Cornell University and completed her PostDoc training as a Leukemia and Lymphoma Society Research Fellow at University of California at San Diego. She was awarded NIH grants to conduct human embryonic stem cell (hESC) research and led the collaborative effort to develop the utility of hESC as a model system for a diverse range of biological and medical problems in one of the NIH exploratory centers for stem cell research. She is a stem cell research innovator with 2 USPTO patents, an Asian American woman entrepreneur, a hESC research advocate, a patient advocate, a minority leader with broad scientific training and extensive stem cell expertise. She is the first to develop the key breakthrough technologies for large-scale production of high quality clinical-grade hESC lines and their functional human neuronal and heart cell therapy derivatives for commercial and therapeutic uses, thus overcoming the major bottleneck in the regenerative medicine market and enabling therapeutic development, commercialization, and clinical practice of hESC tools and products. In regenerative medicine, hESC research holds huge promise for treating major human diseases that have been challenging for traditional medicine. Her original hESC research breakthroughs render neuronal/cardiac lineage-specific conversion directly from the pluripotent state of hESC by small molecule induction, which opens the door for human neural/cardiac tissue/organ engineering/regeneration and investigating molecular human embryonic development using powerful in vitro model systems. Her breakthrough medical innovations and advocacy have contributed to improving policy making for hESC research in the Federal Government. She has strived to gain equitable access and recognition for women in a field dominated by men, to improve leadership prospects for women, to fight for fair treatments for underserved minority communities, to fight for millions of patients and for their rights and their hopes to access to potential life-saving treatments and cures brought by the therapeutic potential of hESC and the breakthrough medical innovations of her hESC research, to alert the harms of adult stem cell Ponzi schemes or scams, such as so-called induced pluripotent stem/adult cells (iPSC) that are in fact adult cells reprogrammed with oncogenes or cancer cells, to the government and exposed patients, and to advocate transparent and responsible funding for stem cell research.
Human Embryonic Stem Cell Patents
USPTO# 8,716,017, “Technologies, Methods, & Products of Small Molecule-Directed Tissue & Organ Regeneration from Human Pluripotent Stem Cells”. First U.S. patent for large-scale production of clinical-grade high quality human embryonic stem cell lines and their neuronal cell therapy products.
USPTO# 9,428,731, “Technologies, Methods, & Products of Small Molecule-Directed Tissue & Organ Regeneration from Human Pluripotent Stem Cells”. First U.S. patent for large-scale production of clinical-grade high quality human embryonic stem cell lines and their heart muscle cell therapy products.